GlassScriptPhysician profile
Aimee D Guidry
NPI 1679673412
$1,694.77
in general payments reported to CMS, 2019-2025
17 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $608 · 2022: $291 · 2023: $298 · 2024: $204 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $262.27 | 2021-2025 | Trintellix |
| Novo Nordisk INC | $238.69 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $160.99 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $150.04 | 2021-2023 | |
| Amgen INC. | $149.34 | 2021-2024 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.79 | 2021-2025 | Jardiance |
| Corium, LLC | $129.81 | 2022-2025 | Azstarys |
| Abbott Laboratories | $99.19 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $97.80 | 2021-2024 | Airsupra, Breztri |
| Boston Scientific Corporation | $72.48 | 2021 | |
| Phathom Pharmaceuticals, INC. | $48.15 | 2024-2025 | Voquezna |
| Dexcom, INC. | $39.77 | 2021 | |
| Axsome Therapeutics, INC. | $30.00 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $21.16 | 2025 | |
| Exact Sciences Corporation | $18.20 | 2025 | Cologuard Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.96 | 2025 | Xifaxan |
| Pfizer INC. | $15.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Guidry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.